Mini-Reviews in Medicinal Chemistry

Author(s): Yan Lavrovsky, Yan A. Ivanenkov, Konstantin V. Balakin, Darya A. Medvedeva and Alexandre V. Ivachtchenko

DOI: 10.2174/138955708785909907

DownloadDownload PDF Flyer Cite As
CXCR4 Receptor as a Promising Target for Oncolytic Drugs

Page: [1075 - 1087] Pages: 13

  • * (Excluding Mailing and Handling)

Abstract

There has been considerable in vivo evidence that chemokine receptor CXCR4 and its endogenous ligand CXCL12 modulate some important physiological and pathophysiological processes, including cancer metastasis, angiogenesis, invasion, growth and progression. In this review we elucidate key aspects of CXCL12-CXCR4 signaling system with emphasis on peptide-based and small-molecule CXCR4 inhibitors.

Keywords: Chemokine, chemokine receptor, CXCR4, CXCL12, SDF-1, tumor, cancer, drugs, inhibitors, antagonists